These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 17454337

  • 1. Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma.
    Liebhaber M, Dyer Z.
    J Asthma; 2007 Apr; 44(3):195-6. PubMed ID: 17454337
    [No Abstract] [Full Text] [Related]

  • 2. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients.
    Domingo C, Moreno A, José Amengual M, Montón C, Suárez D, Pomares X.
    Curr Med Res Opin; 2011 Jan; 27(1):45-53. PubMed ID: 21083517
    [Abstract] [Full Text] [Related]

  • 3. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A.
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [Abstract] [Full Text] [Related]

  • 4. Use of omalizumab in a severe asthma clinic.
    Gibson PG, Taramarcaz P, McDonald VM.
    Respirology; 2007 Nov; 12 Suppl 3():S35-44; discussion S45-7. PubMed ID: 17956518
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H.
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.
    Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, Buhl R.
    Ann Allergy Asthma Immunol; 2010 Oct; 105(4):313-9. PubMed ID: 20934632
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A, Sternon J.
    J Pharm Belg; 2006 Oct; 61(3):83-7. PubMed ID: 17058881
    [Abstract] [Full Text] [Related]

  • 9. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW, Massanari M, Kianifard F, Geba GP.
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [Abstract] [Full Text] [Related]

  • 10. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M, Tonnel AB.
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [Abstract] [Full Text] [Related]

  • 11. [Biotherapies for the treatment of asthma: are they the treatment of the future?].
    Tonnel AB, Denis G, Lelong J.
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S44-10S48. PubMed ID: 17127963
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 13. [Omalizumab (Xolair). Product description].
    Laursen LC.
    Ugeskr Laeger; 2007 Mar 12; 169(11):993-5. PubMed ID: 17371630
    [Abstract] [Full Text] [Related]

  • 14. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
    Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R.
    Respir Med; 2009 Nov 12; 103(11):1725-31. PubMed ID: 19515548
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.
    Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M.
    J Asthma; 2011 May 12; 48(4):387-92. PubMed ID: 21391878
    [Abstract] [Full Text] [Related]

  • 16. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D.
    Respir Med; 2006 Nov 12; 100(11):1907-17. PubMed ID: 16949266
    [Abstract] [Full Text] [Related]

  • 17. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R.
    Ther Adv Respir Dis; 2008 Dec 12; 2(6):409-21. PubMed ID: 19124386
    [Abstract] [Full Text] [Related]

  • 18. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):302-7. PubMed ID: 16464445
    [Abstract] [Full Text] [Related]

  • 19. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
    Dodig S, Richter D, Cepelak I, Benko B.
    Acta Pharm; 2005 Jun 08; 55(2):123-38. PubMed ID: 16179127
    [Abstract] [Full Text] [Related]

  • 20. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R.
    Curr Med Res Opin; 2011 Nov 08; 27(11):2223-8. PubMed ID: 21933100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.